does medicare cover glp 1 for cardiovascular disease A New Use Wegovy Opens the Door to Coverage for Millions of People with Obesity Medicare just made one of

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda) were built for diabetes and obesitybut theyre increasingly being studied for brain health and systemic inflammation.

2026 is shaping-up to be a massive year for GLP-1 drugs...the next driver of global user TAM will be kicking-off in Canada later this year w/generic Semaglutide

Methods We conducted a systematic review of prospective studies reporting T with and without GLP-1 RA treatment

Earlier initiation is reshaping patient journeys: Patients are starting GLP1 therapy within weeks of diagnosis, underscoring the need for streamlined access pathways and payer alignment to reduce delays, especially in Medicare populations

It was not until February 2023 that once-weekly SC semaglutide 2.4 mg (Wegovy®) was approved for obesity treatment, and in the following month, tirzepatide (Mounjaro®) received approval for the treatment of T2D

Carmot gets $150 million to finance its obesity pipeline